Integrated CDMO AAIPharma Services Corp./ Cambridge Major Laboratories, now Alcami, offers integrated drug product, lab services, and API development and manufacturing capabilities, enabling clients to partner with a single provider from development through commercial scale. Opportunity: target mid-market biopharma and specialty pharma seeking an all-in-one CDMO to streamline vendor management and accelerate time-to-market with an integrated service model.

Expansion History Historical growth through facility expansions, including a 40,000-square-foot expansion in 2012 and a Philadelphia site opening, signals capacity to support growing programs and scale-up needs. Sales angle: approach growth-stage companies planning capacity expansions or site relocations in the US that need rapid access to manufacturing and development resources.

Regional Footprint Strategic regional footprint in Wilmington, NC, and Philadelphia offers US-based coverage across Southeast and Northeast markets, enabling closer collaboration and faster supply chain responsiveness. Sales angle: target pharma and biotech firms in these regions seeking regional CDMO partners with capable development and manufacturing capabilities.

Alcami Synergy Alcami integration provides access to a broader network for drug product, lab services, and API development/manufacturing, enabling cross-sell opportunities and end-to-end project execution under one organization. Sales angle: position as a turnkey partner for programs requiring seamless handoffs from development to manufacturing and potential multi-site scaling.

Financial Readiness Mid-market revenue range of 250–500 million with a 20 million funding backdrop indicates established operations with investment capacity to support new programs, capacity expansions, and continuous improvement. Sales angle: pitch long-term partnerships with predictable funding and capability expansion to support pipeline growth and regulatory readiness.